DNA hypermethylation in tumorigenesis: Epigenetics joins genetics

Trends in Genetics

Volumn 16, Issue 4, 2000, Pages 168-174

  Baylin, Stephen B ^a   Herman, James G ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER SUSCEPTIBILITY; CARCINOGENESIS; CHROMATIN; CPG ISLAND; DNA METHYLATION; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; GENE INACTIVATION; GENE MUTATION; GENE SILENCING; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; RAT; REVIEW; TUMOR SUPPRESSOR GENE;

DNA METHYLATION; DNA, NEOPLASM; HUMANS; NEOPLASMS;

EID: 0034176798     PISSN: 01689525     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-9525(99)01971-X     Document Type: Review

References (75)

1. Kinzler K.W., Vogelstein B. Landscaping the cancer terrain. Science. 280:1998;1036-1037.
2. Ng H.-H., Bird A. DNA methylation and chromatin modification. Curr. Opin. Genet. Dev. 9:1999;158-163.
3. Bestor T.H., Tycko B. Creation of genomic methylation patterns. Nat. Genet. 12:1996;363-367.
4. Surani M.A. Imprinting and the initiation of gene silencing in the germ line. Cell. 93:1998;309-312.
5. Baylin S.B. Alterations in DNA methylation: A fundamental aspect of neoplasia. Klein G., Van de Woude G.F. Advances in Cancer Research. 1998;141-196 Academic Press.
6. Jones P.A., Laird P.W. Cancer epigenetics comes of age. Nat. Genet. 21:1999;163-167.
7. Herman J.G.et al. Silencing of the VHL tumor suppressor gene by DNA methylation in renal carcinoma. Proc. Natl. Acad. Sci. U. S. A. 91:1994;9700-9704.
8. Sherr C.J. Cancer cell cycles. Science. 274:1996;1672-1677.
9. Kamb A.et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 264:1994;436-440.
10. Herman J.G.et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 55:1995;4525-4530.
11. Aaltonen L.A.et al. Clues to the pathogenesis of familial colorectal cancer. Science. 260:1993;812-816.
12. Thibodeau S.N.et al. Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes. Cancer Res. 56:1996;4836-4840.
13. Herman J.G.et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci. U. S. A. 95:1998;6870-6875.
14. Xu C.F., Solomon E. Mutations of the BRCA1 gene in human cancer. Semin. Cancer Biol. 7:1996;33-40.
15. Esteller M.et al. Promoter hypermethylation is a cause of BRCA1 inactivation in sporadic breast and ovarian tumors. J. Natl. Cancer Inst. 2000;(in press).
16. Yoshiura K.et al. Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc. Natl. Acad. Sci. U. S. A. 92:1995;7416-7419.
17. Graff J.R.et al. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res. 55:1995;5195-5199.
18. Graff J.R.et al. Distinct patterns of E-cadherin CpG island methylation in papillary, follicular, Hurthle's cell, and poorly differentiated human thyroid carinoma. Cancer Res. 58:1998;2063-2066.
19. Kane M.F.et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res. 57:1997;808-811.
20. Esteller M.et al. MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene. 17:1998;2413-2417.
21. Leung S.Y.et al. hMLH1 promoter methylation and lack of hMLH1 expression in sporadic gastric carcinomas with high-frequency microsatellite instability. Cancer Res. 59:1999;159-164.
22. Esteller M.et al. Epigenetic inactivation of LKB1 in primary tumors associated with the Peutz-Jeghers syndrome. Oncogene. 19:2000;164-168.
23. Herman J.G.et al. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15(INK4B). Cancer Res. 56:1996;722-727.
24. Corn P.G.et al. Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5′ CpG island methylation. Cancer Res. 59:1999;3352-3356.
25. Kawano S.et al. Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation. BLOOD. 94:1999;1113-1120.
26. Batova A.et al. Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia. Cancer Res. 57:1997;832-836.
27. Ottaviano Y.L.et al. Methylation of the estrogen receptor gene CpG island marks loss of estrogen expression in human breast cancer cells. Cancer Res. 54:1994;2552-2555.
28. Issa J.P.et al. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat. Genet. 7:1994;536-540.
29. Esteller M.et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 59:1999;793-797.
30. Lee W.H.et al. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc. Natl. Acad. Sci. U. S. A. 91:1994;11733-11737.
31. Esteller M.et al. Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. Cancer Res. 58:1998;4515-4518.
32. Bachman K.E.et al. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggests a suppressor role in kidney, brain and other human cancers. Cancer Res. 59:1999;798-802.
33. Katzenellenbogen R.et al. Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. BLOOD. 93:1999;4347-4353.
34. INK4a is an early event in lung cancer and a potential biomarker for early diagnosis. Proc. Natl. Acad. Sci. U. S. A. 95:1998;11891-11896.
35. Wong D.J.et al. Progressive region-specific de novo methylation of the p16 CpG island in primary human mammary epithelial cell strains during escape from Mo growth arrest. Mol. Cell Biol. 19:1999;5642-5651.
36. Nuovo G.J.et al. In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis. Proc. Natl. Acad. Sci. U. S. A. 96:1999;12754-12759.
37. Kiyono T.et al. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithlial cells. Nature. 396:1998;6706.
38. Esteller M.et al. hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis. Am. J. Pathol. 155:1999;1767-1772.
39. Myohanen S.K.et al. Hypermethylation can selectively silence individual p16ink4A alleles in neoplasia. Cancer Res. 58:1998;591-593.
40. Jones P.L.et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat. Genet. 19:1998;187-191.
41. Nan X.et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature. 393:1998;386.
42. Wade P.A.et al. Mi-2 complex couples DNA methylation to chromatin remodelling and histone deacetylation. Nat. Genet. 23:1999;62-66.
43. Ng H.-H.et al. MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex. Nat. Genet. 23:1999;58-61.
44. Cameron E.E.et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 21:1999;103-107.
45. Mannervik M.et al. Transcriptional coregulators in development. Science. 284:1999;606-609.
46. Struhl K. Histone acetylation and transcriptional regulatory mechanisms. Genes Dev. 12:1998;599-606.
47. Toyota M.et al. CpG island methylator phenotype in colorectal cancer. Proc. Natl. Acad. Sci. U. S. A. 96:1999;8681-8686.
48. Melki J.R.et al. Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. Cancer Res. 59:1999;3730-3740.
49. INK4A methylation and p53 mutational status. Cancer Res. 60:1999;129-133.
50. Esteller M.et al. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 59:1999;67-70.
51. Beard C.et al. Loss of methylation activates Xist in somatic but not in embryonic cells. Genes Dev. 9:1995;2325-2334.
52. Li E. Role of DNA methylation in development in genomic imprinting. Reik W., Surani A. Frontiers in Molecular Biology. 1997;1-20 IRL Press.
53. Okano M.et al. Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nat. Genet. 19:1998;219-220.
54. Okano M.et al. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell. 99:1999;247-257.
55. Lengauer C.et al. DNA methylation and genetic instability in colorectal cancer cells. Proc. Natl. Acad. Sci. U. S. A. 94:1997;2545-2550.
56. Robertson K.D.et al. The human DNA methyltransferases (DNMTs) 1, 3a and 3b. coordinate mRNA expression in normal tissues and overexpression in tumors Nucleic Acids Res. 27:1999;2291-2298.
57. Wu J.et al. Expression of an exogenous eukaryotic DNA methyltransferase gene induces transformation of NIH 3T3 cells. Proc. Natl. Acad. Sci. U. S. A. 90:1993;8891-8895.
58. Bakin A.V., Curran T. Role of DNA 5-methylcytosine transferase in cell transformation by fos. Science. 283:1999;387-390.
59. Laird P.W.et al. Suppression of intestinal neoplasia by DNA hypomethylation. Cell. 81:1995;197-205.
60. MacLeod A.R., Szyf M. Expression of antisense to DNA methyltransferase mRNA induces DNA demethylation and inhibits tumorigenesis. J. Biol. Chem. 270:1995;8037-8043.
61. Vertino P.M.et al. De Novo methylation of CpG island sequences in human fibroblasts overexpressing DNA (cytosine-5-)-methyltransferase. Mol. Cell Biol. 16:1996;4555-4565.
62. Rhee I.et al. CpG methylation is maintained in cancer cells lacking DNMT. Nature. 2000;(in press).
63. Macleod D.et al. An alternative promoter in the mouse major histocompatibility complex class II I-Abeta gene. implications for the origin of CpG islands Mol. Cell Biol. 18:1998;4433-4443.
64. Brandeis M.et al. Sp1 elements protect a CpG island from de novo methylation. Nature. 29:1994;435-538.
65. Macleod D.et al. Sp1 sites in the mouse aprt gene promoter are required to prevent methylation of the CpG island. Genes Dev. 8:1994;2282-2292.
66. Marin M.et al. Transcription factor Sp1 is essential for early embryonic development but dispensable for cell growth and differentiation. Cell. 4:1997;619-628.
67. Siegfried Z.et al. DNA methylation represses transcription in vivo. Nat. Genet. 22:1999;203-206.
68. Pollard K.J., Peterson C.L. Chromatin remodeling: a marriage between two families? BioEssays. 20:1998;771-780.
69. Jeddeloh J.A.et al. Maintenance of genomic methylation requires a SWI2/SNF2-like protein. Nat. Genet. 22:1999;94-97.
70. Herman J.G.et al. Methylation-specific PCR. A novel PCR assay for methylation status of CpG islands Proc. Natl. Acad. Sci. U. S. A. 93:1996;9821-9826.
71. Sadri R., Hornsby P.J. Rapid analysis of DNA methylation using new restriction enzyme sites created by bisulfite modification. Nucleic Acids Res. 24:1996;5058-5059.
72. Wong I.H.N.et al. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res. 59:1999;71-73.
73. Momparler R.L.et al. Pharmacological approach for optimization of the dose schedule of 5-Aza-2′-deoxycytidine (Decitabine) for the therapy of leukemia. Leukemia. 11:1997;S1-S6.
74. Juttermann R.et al. Toxicity of 5-aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc. Natl. Acad. Sci. U. S. A. 91:1994;11797-11801.
75. Ferguson A.T.et al. Role of estrogen receptor gene demethylation and DNA methyltransferase DNA adduct formation in 5-Aza-2′-deoxycytidine-induced cytotoxicity in human breast cancer cells. J. Biol. Chem. 272:1997;32260-32266.